Tag: Multiple Sclerosis
Medicare Patients With MS Face Higher Out-of-Pocket Rx Costs
Projected cumulative out-of-pocket spending for disease-modifying therapies for 2019 was $6,894
Management of MS in Pregnancy Reviewed in U.K. Guideline
Pros and cons of continuing treatment throughout pregnancy should be discussed individually
Risk for Conversion of MS Varies With Different Therapies
Lower risk for conversion for initial treatment with fingolimod, alemtuzumab, or natalizumab
Risk for Conversion of MS Varies With Different Therapies
Lower risk for conversion for initial treatment with fingolimod, alemtuzumab, or natalizumab
Stem Cell Transplant Slows Progression of Multiple Sclerosis
Findings from small randomized trial comparing nonmyeloablative HSCT with disease-modifying tx
Rituximab Beneficial in Secondary Progressive MS
Treatment with rituximab linked to lower Expanded Disability Status Scale score, delayed progression
Food Allergy Linked to Increased Multiple Sclerosis Activity
More attacks, higher odds of gadolinium-enhancing lesions for food allergy versus no known allergy
Palliative Care in MS Inpatients Rises From 2005 to 2014
Palliative care linked to increased length of stay and in-hospital death, decreased hospital charges
Certain Sites of Brain Lesions in MS Tied to Bowel Incontinence
Left hemisphere dominates sensory visceral integration, right tied to the autonomic function
FDA Warns of Rare Stroke Risk With Multiple Sclerosis Drug
Alemtuzumab label will be updated to include the risk for stroke and arterial dissection
